Universe Pharmaceuticals vs Viatris
Universe Pharmaceuticals is the larger business, with $17.86bn of revenue in fiscal 2025 against $14.30bn for Viatris (1.2 times as much). Viatris grew faster (-3.0% against -22.4%). Universe Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -20.6% against -24.6%. Universe Pharmaceuticals carries less debt relative to equity (16.5% against 98.0%).
| Latest fiscal year | Universe PharmaceuticalsUPC, 2025 | ViatrisVTRS, 2025 |
|---|---|---|
| Revenue | $17.86bn | $14.30bn |
| Revenue growth | -22.4% | -3.0% |
| Net income | −$3.67bn | −$3.51bn |
| Operating margin | -16.3% | -18.6% |
| Net margin | -20.6% | -24.6% |
| Return on equity | -7.2% | -21.1% |
| Free cash flow | −$5.32bn | $1.94bn |
| Cash | $33.59bn | $1.32bn |
| Total debt | $9.26bn | $14.41bn |
| Debt to equity | 16.5% | 98.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $501m |
| Employees | — | 30,000 |
| Market value | $844,444 | $21.83bn |
| Price vs our value range | — | Within our value range |
| Moat score | — | 42 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 2 sales |